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Abstract
Background: Aggressive course and resistance to treatments usually characterize very early onset inflammatory
bowel disease (VEO-IBD). Some VEO-IBD cases are due to monogenic immune defects and can benefit from
hematopoietic stem cell transplantation (HSCT).
Case presentation: We describe a Caucasian male baby who presented in the first months of life macrophage
activation syndrome, followed by intractable colitis, recurrent episodes of fever and mild splenomegaly. After
several immunological, genetic and clinical investigations, subsequently a therapeutic attempt with colectomy,
analysis of VEO-IBD-associated genes, revealed a causative mutation in XIAP. The genetic diagnosis of a primary
immune deficiency allowed curing the boy with hematopoietic stem cell transplantation.
Conclusion: Our report, together with novel findings from recent literature, should contribute to increase
awareness of monogenic immune defects as a cause of VEO-IBD. Comprehensive genetic analysis can allow a prompt
diagnosis, resulting in the choice of effective treatments and sparing useless and damaging procedures.
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Background
Very early onset inflammatory bowel disease (VEO-IBD)
is a rare and usually severe disorder, distinct from adult
disease as regards extension, histopathology and treat-
ment. A primary immunodeficiency (PID) may be the
cause of the disease in a not negligible proportion of cases
[1, 2]. Notably, gut inflammation can be the first and sole
clinical manifestation of a PID for several years, while
infections can develop later or remain underestimated.
Indeed, IBD or IBD-like inflammation can be often the
sole or the first manifestation of Chronic Granuloma-
tous Disease (CGD) [3, 4], Wiskott Aldrich Disease [5],
NEMO deficiency [6] or Polyendocrinopathy Enteropathy
X-linked (IPEX) [7]. Recently also IL10R [8] and
XIAP deficiencies [9] have been reported in children
with early onset colitis, expanding the “universe of
primary immunodeficiency” in IBD. Early onset IBD
can be also presenting feature of autoinflammatory
disorders, such as mevalonate kinase deficiency (MKD)
[10, 11]. Moreover, functional studies have shown that
VEO-IBD can occur in patients with TTC7A gene muta-
tions, causing defects in the enterocytes and in T cells,
giving rise to the development of a severe apoptotic en-
terocolitis [12]. Diagnosis of monogenic causes of early
and very early onset-IBD is important in cases that could
benefit from hematopoietic stem cell transplantation
(HSCT). It is thus important to increase awareness of the
possible monogenic etiology of VEO-IBD among pediatri-
cians, promoting the development of reliable strategies for
a prompt and thorough differential diagnosis.
Case presentation
We report the case of a male baby, born to non-
consanguineous healthy parents, who was hospitalized at
2 months of age with mucous and bloody diarrhea, fever
and failure to thrive. The medical history revealed that
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he was admitted at the same hospital 1 month before be-
cause of high fever and hepatosplenomegaly that were
attributed to a cytomegalovirus (CMV) infection with
macrophage activation syndrome (MAS) (Table 1).
In spite of the absence of hemophagocytosis at the
bone marrow smear, the main causes of familial lympho-
histiocytosis were studied, yet with normal results. An
antiviral therapy with ganciclovir, together with high
dose dexamethasone, led to resolution of fever.
When the boy presented to our department, no sign of
MAS was present and CMV was not detected in body
fluids. A colonoscopy showed inflammatory colitis with
erosions and aphthae (Fig. 1); the analysis of mucosal
specimens revealed increased enterocyte apoptosis, lead-
ing to the suspicion of autoimmune enteropathy.
Genetic analysis of the FOXP3 gene, responsible for
IPEX, did not evidence any mutation. Total parenteral
nutrition, tacrolimus and high dose steroids (10 mg/m2)
were administered with good clinical and endoscopic
response.
In the following months, after stopping steroids, in
spite of continuing therapy with tacrolimus, the boy
Table 1 Summary of clinical features and treatments
1 month 2 – 3 months 11.5 months 15 months
Clinical features High fever, High fever Intractable diarrhoea Intractable diarrhoea, Vomit,
Hepatomegaly, Bloody and mucous
diarrhoea
Recurrent fever Recurrent fever
Splenomegaly Failure to thrive Skin rash
Mild splenomegaly Mild hepato-splenomegaly
Haematological values WBC 25.000/μl WBC: 5.140/μl WBC: 31.440/μl WBC: 18.400/μl
(N 38 %) (N29%) (N 55 %) (N 62 %)
CRP: 14,3 mg/L CRP: 21 mg/L CRP: 107 mg/L CRP: 99 mg/L
AST: 219 U/L AST: 47 U/L
ALT: 327 U/L ALT: 41 U/L
LDH 2300 U/L Triglycerides: 2,39 mmol/L
Triglycerides: 3,08 mmol/L Ferritin: 1.651 ng/ml
Ferritin: 18.000 ng/ml
IgA: 0,54 g/L
IgG: 5,67 g/L
IgM: 0,74 g/L
hypoalbumiemia
Specialist investigations Bone marrow smear:
negative
Colonoscopy: inflammatory
colitis with erosions and
aphthae and increased cell
apoptosis
Colonoscopy: Crohn’s-like
colitis
EGDS normal
CMV negative in mucosa
Virology Blood CMV: 435.800 copies/
ml
Blood CMV: negative
Immunological
evaluations
Normal Degranulation Assay DHR test normal
Genetic evaluations PRF1, SAP, STXBP2 wild type FOXP3: wild type MVK: wild type IL10, IL10RA, L10RB: wild
type
XIAP: mutate
Therapeutic interventions Glucocorticoids, ganciclovir Intravenous glucocorticoids,
tacrolimus,
Glucocorticoids, Azathioprine,
Adalimumab
Glucocorticoids,
Adalimumab,
TPN
TPN TPN Antibiotics
Surgical intervention none none Colectomy HSCT
DHR dihydrorhodamine
TPN total parenteral nutrition
HSCT hematopoietic stem cell transplantation
CRP C Reactive Protein: normal values below 10 mg/L also the EGDS acronimous should be added in the legenEGDS Esophagogastroduodenoscopy
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remained dependent on parenteral nutrition because
of severe stunting. He developed several bouts of
fever accompanied by increased acute phase reactants,
worsening of diarrhea, skin rash and mild splenomeg-
aly, but always not fulfilling the diagnostic criteria of
MAS. Colonoscopy showed severe mucosal inflamma-
tion plus colon ulcerations, rectal and sigmoid ery-
thema with fragile mucosa. In addiction edematous
pseudopolypoid lesions and serpiginous ulcer covered
by fibrin exudate have been observed from rectum to
transverse colon. Ascending colon showed areas of
reparative or scar tissue. Histologic examination con-
firmed the presence of a chronic inflammatory infil-
trate in the lamina propria and submucosa with rare
epithelioid granulomas. Terminal ileum was healthy.
Taking into account the novel clinical picture, MKD
was suspected, but no mutation was detected in the
MVK gene. Due to the presence of Crohn’s-like features,
chronic granulomatous disease was also suspected, but
the diagnosis was ruled out by normal results of dihy-
drorhodamine (DHR) flow cytometric assay.
A poor clinical response was obtained with standard
dose glucocorticoids, azathioprine and, subsequently,
with adalimumab (30 mg twice per month, subcutane-
ously). A transitory improvement was observed only
after colectomy, however, recurrence of fever episodes
persisted and the boy soon developed a Crohn’s-like
ileitis.
Further genetic analyses were thus performed, includ-
ing the sequencing of Interleukin (IL)-10 Receptor
(IL10RA and IL10RB), Interlukin-10 (IL10) and X-linked
inhibitor of apoptosis (XIAP) genes. A deletion of two
base-pairs was found in exon 4 of XIAP, causing a frame-
shift and a premature stop codon (RefSeq NM_001167,
c.1021_1022delAA, p.N341YfsX7, Fig. 2a, b) [13]. The
mutation was proven to be causative based on absent ex-
pression of the protein in T lymphocytes analyzed by
flow cytometry with two anti-XIAP antibodies clones
(clone48 BD Biosciences, cloneE-2 Santa Cruz Biotech-
nology). Since XIAP interacts with Nucleotide binding
oligomerization domain 2 (NOD2), we also analyzed
IL-8 production in response to muramyl dipeptide
(MDP), revealing impaired signaling of this pathway
(Fig. 2c, d). Based on the identification of XIAP mutation
and the functional studies performed, the diagnosis
of XIAP deficiency was made, so the patient underwent
allogeneic-HSCT from a group A1 positive, CMV negative
and EBV positive HLA-matched unrelated donor. He re-
ceived peripheral stem cells (12,8x106 CD34+ cells/kg)
after a myeloablative-conditioning regimen as illustrated in
Fig. 3. Nine days after transplantation, gastrointestinal
bleeding with severe anaemia occurred. On day +15, mica-
fungin was administered together with replacement of the
central venous catheter (CVC) because of Candida sepsis.
A CMV infection (+33 days) was successfully treated with
ganciclovir and Foscavir. The patient developed an abso-
lute neutrophil count above 500/μL on day +17 and a
platelet counts above 50.000/μL on day +45. Six months
after transplantation, a gradual improvement of appetite
was observed, allowing the suspension of parenteral
nutrition. The immunosuppressive therapy was interrupted
after 9 months. Both upper endoscopy and ileoscopy were
normal. On the last follow-up (+15 months), after tempor-
ary ileostomy reversal, the patient was found in good
clinical conditions and no symptoms related to XIAP defi-
ciency nor gastrointestinal problems were observed.
Discussion
VEO-IBD can represent a serious diagnostic and thera-
peutic challenge. In our case, a monogenic cause for the
disease was extensively searched because of complex
clinical features such as a CMV-induced macrophage ac-
tivation syndrome, recurrent fever, and intractable
course of the disease.
Fig. 1 Image of colonoscopy investigation. In the pictures is possible to appreciate the colonoscopy features of the patient, in particular the
erosions and apthae.
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Fig. 2 (See legend on next page.)
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A familial haemophagocytic lymphohistiocytosis was
suspected and seemingly ruled out by functional and
genetic analysis as well as by the good response to anti-
viral treatment. Afterwards, the association of early
colitis with recurrent fever, rash and splenomegaly arouse
the suspicion of Mevalonate Kinase Deficiency [10], yet
genetic analysis excluded the presence of the disease.
Only some more months later, when disease relapsed
in spite of colectomy, further genetic investigations were
performed and the pathogenic deletion in XIAP gene
identified.
The pathogenic role of XIAP in haemophagocytic
lymphohistiocytosis is well documented [14, 15], and
probably due to increased apoptosis of T cells during
anti-viral responses [16, 17].
The deletion found in our patient, leading to a func-
tional defect of NOD2 signaling, has been previously
described in two brothers with recurrent lymphohistio-
cytosis but without intestinal inflammation [13]. Fur-
thermore, other XIAP mutations have been described in
cases with IBD [9, 18, 19]. Notably, mutations affecting
BIR-2 domain of XIAP have been associated with impair-
ment of NOD2 signaling [20] and IBD-like manifestations
[19, 21]. Also Aguilar et al. have described a clinical over-
lap between Crohn’s disease and XIAP deficiency-
associated IBD [22].
The XIAP mutation described here can thus explain
both recurrent episodes of fever with mild splenomeg-
aly, which likely represent incomplete bouts of lympho-
histiocytosis, and intractable inflammatory colitis. In
fact, XIAP deficiency is recognized as a highly heteroge-
neous disorder, whose expression probably depends
upon the different type of mutation, environmental and
infectious factors. Thus, although this is a serious pri-
mary immunodeficiency, the indication for HSCT is not
always an easy issue, due to high transplantation related
risks [23]. Nevertheless, recent studies show that idio-
pathic colitis with XIAP deficiency could be successfully
treated with allo-HSCT using a specific conditioning
regimen [24].
(See figure on previous page.)
Fig. 2 Electropherogram and functional test of XIAP mutation. a The Figure shows electopherograms of the mutation (c.1021_1022delAA) in exon
4 of XIAP in genomic DNA of patient, mother (heterozygous) and control (wild type). b Scheme of the protein structure of XIAP: BIR 1, 2, 3 and
RING domains are shown. Black arrow indicates the localization of the mutation found in our patient. The mutation results in the substitution of
the wild-type amino acids NIHLTHSLE with the mutant amino acids YSFNSFT until the stop codon and in the truncation of the protein at 347
amino acid of the 497 wild type protein. c Detection of the XIAP protein by flow cytometry on patient, his mother and in two healthy donors
(male age related with patient and female controls age related with mother). The intracellular staining was performed with two different anti-human
XIAP antibodies that recognize the N-terminal domain (amino acids 1-202) or the C-terminal domain (amino acid 268–426), respectively in the left and
in the right side. The XIAP expression was evaluated on the CD45+ CD3+ cell gate. Grey area in the dashed line represents staining with secondary
antibody alone. d NOD signalling pathway assay was performed testing patient, mother and age matched controls PBMCs unstimulated
(US) or treated with IL-1β and MDP. The integrity of the pathway was measured using an IL-8 ELISA. PBMCs from our Crohn’s like patient
were unable to induce the production of IL-8 after MDP stimulation, compared with wild-type controls and his mother, who carries in
heterozygous the same mutation. The histograms report the mean of the values obtained by two different experiments.
Fig. 3 HSCT drug treatments. The figure illustrates the conditioning regimen administered to the patient before the HSCT and the combined
drugs used for the prevention of graft-versus-host disease.
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Conclusion
We highlight the diagnostic challenge of VEO-IBD, with
particular reference to possible monogenic defects of im-
munity. High-throughput genetic analysis can offer valu-
able option to cope with heterogeneity and severity of
VEO-IBD. In our patient, an earlier genetic diagnosis
could have promoted a timely HSCT, which could have
been able to induce a complete remission, sparing colec-
tomy. Although a sequential functional and genetic ap-
proach has been recommended [22], we suggest that
functional investigations should not delay a promptly
genetic analysis, to allow an early detection of rare
monogenic disorders in children with VEO-IBD. We
don’t have a long follow-up; nevertheless our results
suggest that allo-HSCT is also an effective procedure
for VEO-IBD.
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